secwatch.observer — SEC 8-K summary
======================================

Issuer:     INFINITY PHARMACEUTICALS, INC. (—)
CIK:        0001113148
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001113148-23-000012
Event type: leadership
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Infinity Pharmaceuticals replaces CEO, CMO, and CSO; restructuring charge of $3.9M
--------------------------------------------------------------------------------

- CEO Adelene Perkins and CMO Dr. Robert Ilaria terminated without cause effective Sept 1, 2023; CSO Stephane Peluso also terminated.
- Seth Tasker (former SVP, Chief Business Officer) appointed CEO effective Sept 1, 2023.
- August restructuring adds 3 positions to earlier 21-headcount reduction; expects $3.9M one-time charge ($1.6M cash) in Q3 2023.
- Perkins and Ilaria signed severance agreements (9 months pay vs 12) and consulting deals to find alternative path for eganelisib after terminated MEI Pharma merger.
- $537,876 severance for Perkins; $356,362 for Ilaria; both also receive retention fees and reduced COBRA payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/0001113148-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/infi-20230829.htm
  HTML page:      https://secwatch.observer/filing/0001113148-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer